Compare · ACRV vs LLY
ACRV vs LLY
Side-by-side comparison of Acrivon Therapeutics Inc. (ACRV) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACRV and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.18T, about 15621.6x ACRV ($75.4M).
- Over the past year, ACRV is down 9.1% and LLY is up 56.5% - LLY leads by 65.6 points.
- LLY has been more active in the news (25 items in the past 4 weeks vs 1 for ACRV).
- LLY has more recent analyst coverage (25 ratings vs 11 for ACRV).
- Company
- Acrivon Therapeutics Inc.
- Eli Lilly and Company
- Price
- $1.65-6.27%
- $1257.32+0.45%
- Market cap
- $75.4M
- $1.18T
- 1M return
- -3.24%
- +9.10%
- 1Y return
- -9.12%
- +56.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 1
- 25
- Recent ratings
- 11
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ACRV
- SEC Form 4 filed by Acrivon Therapeutics Inc.
- Chief Business Officer Levin Michaela was granted 30,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Levin Michaela
- Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
- Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
- President and CEO Blume-Jensen Peter sold $30,969 worth of shares (14,036 units at $2.21) (SEC Form 4) to satisfy withholding obligation
- Chief Legal Officer Miller Mary sold $372 worth of shares (185 units at $2.01), decreasing direct ownership by 0.23% to 82,009 units (SEC Form 4) (withholding tax)
- Chief Accounting Officer Peterson Katharine sold $203 worth of shares (101 units at $2.01), decreasing direct ownership by 0.56% to 18,033 units (SEC Form 4) (tax liability)
- Chief Development Officer Gamelin Erick sold $804 worth of shares (400 units at $2.01), decreasing direct ownership by 0.75% to 52,592 units (SEC Form 4) (for tax liability)
- Chief Operating Officer Devroe Eric sold $1,214 worth of shares (604 units at $2.01), decreasing direct ownership by 0.41% to 146,349 units (SEC Form 4) (for tax liability)
Latest LLY
- Lilly confirms date and conference call for third-quarter 2026 financial results announcement
- New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
- Nasdaq Sheds 1.65% as Russell 2000 Sinks to RSI 28, Oil Climbs While Gold and Silver Slide
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Record Highs Beckon for Big Caps as Small Caps Lag and Deal Flow Builds
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity
- SEC Form 3 filed by Eli Lilly and Company
- Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
- Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
- Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease